New data shows COVID-19 hospitalizations and deaths are on track to rise for the first time in months, and the FDA is encouraging Americans to get either the Moderna or Pfizer vaccines over the Johnson & Johnson shot.
U.S. regulators are strictly limiting who can receive Johnson & Johnson’s COVID-19 vaccine due to a rare but serious risk of blood clots.
A new study from the CDC shows the booster from Johnson & Johnson is effective at preventing hospitalizations.
The CDC has updated its recommendations on COVID-19 vaccines after its vaccine advisors met on Thursday. This comes as the Omicron variant continues to spread in the U.S.
Data is still coming in on vaccines versus the Omicron variant.
“I don’t want to hit the panic button but we are strongly encouraging South Carolinians to continue the safety protocols that helped us drive the numbers down from that high point back in September,” Traxler said.
U.S. regulators on Wednesday signed off on extending COVID-19 boosters to Americans who got the Moderna or Johnson & Johnson vaccine and said anyone eligible for an extra dose can get a brand different from the one they received initially.
Federal regulators are expected to authorize the mixing and matching of COVID-19 booster doses this week in an effort to provide flexibility as the campaign for extra shots expands.
A Centers for Disease Control panel will meet to discuss COVID-19 booster shots for Johnson & Johnson and Moderna.
An FDA advisory panel voted to recommend Johnson & Johnson’s booster shots for millions of Americans.
